Tuesday, 17 November 2026
Conditional backing for puberty blockers, Pertussis vaccination coverage dips, Anti-CGRPs linked to pregnancy risk
- 01
NHMRC conditionally backs puberty blockers for gender-diverse youth
Puberty suppressants should remain available as a clinical option for people aged under 18 with gender incongruence, according to interim NHMRC advice. The conditional recommendation applies after puberty has commenced and the young person has been assessed as suitable, with treatment decided jointly by the young person, their parents or carers, and clinicians. The NHMRC said treatment must be individualised and may offer time for discussion and decision-making, while withholding care as puberty progresses may affect physical and mental health, wellbeing and functioning. The advice follows restrictions on gender-affirming treatment for minors in Queensland and the Northern Territory, although public gender services remain the responsibility of states and territories. Public consultation is open, with full national clinical guidelines expected in 2028.
via RACGP newsGP
- 02
Pertussis vaccination among one-year-olds falls below 90%
Pertussis vaccination coverage among Australian one-year-olds fell below 90% for the first time since 2000, according to Australian Immunisation Register data. Eight areas between the NSW Northern Rivers and the upper Sunshine Coast recorded rates as much as 35% below the nation’s best-performing areas, with Noosa Hinterland lowest at 63.9%. Weston Creek, Pennant Hills and North Canberra each exceeded 96.5% coverage. National coverage among adolescents turning 15 also fell from 82.5% in 2024 to 80.6% in 2026. The National Notifiable Disease Surveillance System received 9437 pertussis notifications to 12 November 2026, while infectious diseases physician Professor Tom Snelling said geographically concentrated coverage gaps can increase outbreak risk.
- 03
Anti-CGRP exposure linked to higher spontaneous abortion risk
Pregnancy exposure to anti-CGRP monoclonal antibodies was associated with a 42% higher likelihood of spontaneous abortion by 20 weeks compared with no exposure in a US retrospective cohort study. Among 7579 pregnancies, including 350 exposed to anti-CGRP agents, the adjusted risk was 28.7% with exposure versus 24.5% without exposure, a difference of 4.2 percentage points. No association was found for propranolol, which was used as a comparator. The researchers said the findings may not generalise beyond commercially insured US women and acknowledged that the claims data may have underreported spontaneous abortions. They called for further research and said clinicians should consider the limited pregnancy safety evidence when discussing anti-CGRP treatment with people who may become pregnant.
- 04
Federal funding backs national childhood asthma prevention initiative
Asthma Australia received $11.55 million in federal funding for a national initiative focused on preventing asthma attacks and improving long-term outcomes for children and young people. Healthy Lungs for Life will run for three-and-a-half years through the Australian Government’s Chronic Conditions Prevention and Integrated Care grants program. Its five areas of work include a national asthma information hub, healthier lifestyles and reduced tobacco exposure, support at key life stages, and targeted resources for families facing barriers to care. The initiative will also integrate an evidence-based clinical decision support tool into GP software and provide healthcare professional education, with particular attention to culturally and linguistically diverse communities and people in regional and remote Australia.
- 05
Cretostimogene cut bladder cancer recurrence risk in phase 3 trial
Cretostimogene reduced the relative risk of bladder cancer recurrence by 68% versus standard surveillance after surgery in a phase 3 trial. The experimental oncolytic virus immunotherapy was tested in people with intermediate-risk and high-grade non-muscle invasive bladder cancer, with 17 months of follow-up. Safety findings were consistent with previous testing, with no severe or worse drug-related adverse events and no treatment discontinuations due to side effects. CG Oncology said the results met the trial’s primary objective and would support a regulatory application next year, with more detailed data due at a medical meeting next month.
via BioPharma Dive
- 06
Federal department drops preventable hospitalisations performance measure
The Department of Health, Disability and Ageing has dropped potentially preventable hospitalisations as a performance measure for primary care and Primary Health Networks. The measure, introduced five years ago, was replaced with broader PHN analysis after last year’s target was not achieved, with declines recorded in only two PHNs against a target of 28. Planned replacement metrics covering mental health, aged care and drug and alcohol services have also been sidelined, leaving no system-wide PHN performance measure in the department’s annual report for the next two years. Instead, three PHNs will undergo case-study analysis of how effectively they supported general practices in their regions. The latest AIHW data recorded 2617 potentially preventable hospitalisations per 100,000 people, with raw numbers increasing across all PHN areas except Tasmania.
via RACGP newsGP
MDDR is a news digest for medical professionals. It is not medical advice and should not be relied on for clinical decision-making.